Ataxia News and Research RSS Feed - Ataxia News and Research

Ataxia is a neurological sign and symptom that consists of gross lack of coordination of muscle movements. Ataxia is a non-specific clinical manifestation implying disfunction of the parts of the nervous system that coordinate movement, such as the cerebellum.
Northwestern University scientists identify gene important to morning wake-up call

Northwestern University scientists identify gene important to morning wake-up call

Northwestern University scientists have shown a gene involved in neurodegenerative disease also plays a critical role in the proper function of the circadian clock. [More]
Novel drug may increase the effectiveness of radiation therapy for brain cancer

Novel drug may increase the effectiveness of radiation therapy for brain cancer

A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy. [More]
Disease-in-a-dish models show promise for treating ataxia telangiectasia

Disease-in-a-dish models show promise for treating ataxia telangiectasia

Led by Dr. Peiyee Lee and Dr. Richard Gatti, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have used induced pluripotent stem cells to advance disease-in-a-dish modeling of a rare genetic disorder, ataxia telangiectasia. [More]
Researchers identify genetic mutations that appear to underlie rare syndrome

Researchers identify genetic mutations that appear to underlie rare syndrome

Researchers from Massachusetts General Hospital and Duke University have identified genetic mutations that appear to underlie a rare but devastating syndrome combining reproductive failure with cerebellar ataxia - a lack of muscle coordination - and dementia. [More]
Research discovery may lead to effective new treatments for neurodegenerative disease

Research discovery may lead to effective new treatments for neurodegenerative disease

UCLA researchers led by Drs. Peiyee Lee and Richard Gatti at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have used induced pluripotent stem cells to advance disease-in-a-dish modeling of a rare genetic disorder, Ataxia Telangiectasia. [More]
Study results support new view of molecules important for nerve cell signaling

Study results support new view of molecules important for nerve cell signaling

National Institutes of Health researchers used the popular anti-wrinkle agent Botox to discover a new and important role for a group of molecules that nerve cells use to quickly send messages. [More]
ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections. [More]
Abnormal protein translation leads to Fragile X ataxia, study finds

Abnormal protein translation leads to Fragile X ataxia, study finds

A bizarre twist on the usual way proteins are made may explain mysterious symptoms in the grandparents of some children with mental disabilities. [More]
Baylor University study shows acute dose of alcohol may cause greater impairment in elderly

Baylor University study shows acute dose of alcohol may cause greater impairment in elderly

An acute dose of alcohol may cause greater impairment in coordination, learning and memory in the elderly than in young people, according to a study by Baylor University. [More]
Dysfunction of Calcium channel in neurons of cerebellum causes different motor diseases

Dysfunction of Calcium channel in neurons of cerebellum causes different motor diseases

A dysfunction of a certain Calcium channel, the so called P/Q-type channel, in neurons of the cerebellum is sufficient to cause different motor diseases as well as a special type of epilepsy. [More]
Fast-progressing hearing impairment linked to fatal Creutzfeldt-Jakob Disease

Fast-progressing hearing impairment linked to fatal Creutzfeldt-Jakob Disease

Rapid hearing loss in both ears may be a symptom of the rare but always-fatal Creutzfeldt-Jakob Disease and should be considered a reason for clinicians to test for the disorder. [More]
Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

What is the cost of rare diseases such as Friedreich's Ataxia? By analyzing direct and indirect costs of care research in BioMed Central's open access journal Orphanet Journal of Rare Diseases calculated that conservatively this rare disease costs between £11,000 and £19,000 per person per year. [More]
Researchers to develop new diagnostic tools and treatments for people with rare diseases

Researchers to develop new diagnostic tools and treatments for people with rare diseases

A multi-million Euro initiative is bringing together researchers from across the world to develop new diagnostic tools and new treatments for people with rare diseases and to connect research data in this area on a global scale. [More]

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland. [More]
Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia." [More]
JPND invites proposals from researchers to understand the underlying causes of neurodegenerative diseases

JPND invites proposals from researchers to understand the underlying causes of neurodegenerative diseases

The EU Joint Programme - Neurodegenerative Disease Research (JPND) is inviting calls for proposals from research teams across Europe to increase understanding of the factors that put people at risk of developing neurodegenerative diseases (ND) such as Alzheimer's and also to evaluate health and social care strategies for people living with these debilitating illnesses. [More]

Parasympathetic dysfunction underpins Gulf War Syndrome

Gulf War veterans with self-reported symptoms of autonomic dysfunction have objective evidence of underlying damage to central and peripheral cholinergic function, a study shows. [More]
DLKI-DIO3 miRNA cluster suppresses spread of cancer from its primary site

DLKI-DIO3 miRNA cluster suppresses spread of cancer from its primary site

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered a group of what have been considered relatively minor regulators in the body that band together to suppress the spread of cancer from its primary site. [More]
UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4. [More]

Spaniels' neuropathic pain condition stays static without surgery

Cavalier King Charles with neuropathic pain induced by a condition characterized by a brain–skull size mismatch do not show significant improvement after nonsurgical treatment for the condition, indicate UK study results. [More]